A 16-amino acid peptide encoded in mitochondrial DNA that activates AMPK, drives metabolic homeostasis, and replicates key molecular benefits of physical exercise.
Last updated: March 2026 · Research status: Early-Phase Human Trials
Mechanism of Action
MOTS-c is one of a handful of known mitochondrial-derived peptides (MDPs). Its unique biology bridges mitochondrial metabolism and systemic hormonal signaling.
MOTS-c is translated from an open reading frame within the 12S rRNA gene of mitochondrial DNA — making it the first mtDNA-encoded peptide shown to act as a systemic hormone. Unlike nuclear-encoded peptides, it originates directly from the cell's ancient energy organelle.
MOTS-c enters the nucleus and regulates gene expression by disrupting one-carbon metabolism (folate cycle) and purine biosynthesis. This creates AMP/ATP ratio shifts that activate AMPK — the master energy sensor of the cell, the same switch triggered by exercise and caloric restriction.
AMPK activation by MOTS-c drives downstream metabolic effects: enhanced glucose uptake via GLUT4 translocation, increased fatty acid oxidation, improved insulin sensitivity, and reduced ectopic fat accumulation. It restores metabolic balance disrupted by age or high-fat diet.
MOTS-c is released from mitochondria in response to metabolic stress and physical exercise, then travels systemically via the bloodstream. It acts as a retrograde signal — communicating mitochondrial status to the rest of the body and coordinating a global adaptive metabolic response.
Under cellular stress, MOTS-c translocates from cytoplasm to the nucleus and directly binds ARE (antioxidant response element) gene targets. This drives NRF2-pathway activation, upregulating antioxidant defenses, mitochondrial biogenesis, and anti-inflammatory gene programs.
MOTS-c treatment in mouse models with diet-induced obesity restores insulin sensitivity comparable to metformin. The mechanism involves AMPK-driven GLUT4 expression and inhibition of IRS-1 serine phosphorylation — a key defect in insulin resistance and type 2 diabetes.
Exercise Mimetic Properties
MOTS-c is elevated by physical exercise and mediates many of its molecular benefits. Exogenous MOTS-c in animal models recapitulates key exercise adaptations.
Cross-trial comparison note: Data above is from rodent studies. Values are indicative of effect direction and magnitude — not directly translatable to human outcomes. No head-to-head human RCT data available as of 2026.
Age-Related Decline
Circulating MOTS-c levels follow a predictable decline with aging and physical inactivity — paralleling the metabolic deterioration seen across these same periods of life.
MOTS-c production declines as mitochondrial function deteriorates with age. Fewer functional mitochondria, reduced mtDNA copy number, and impaired mitochondrial membrane potential all contribute. Physical inactivity accelerates this decline — exercise is the strongest known natural stimulus for MOTS-c secretion.
The pattern of MOTS-c decline tracks closely with age-related metabolic dysfunction: rising insulin resistance, declining muscle mass, accumulating ectopic fat. This correlation has fueled speculation that MOTS-c depletion may causally contribute to metabolic aging — not merely accompany it.
Research Evidence
MOTS-c research has progressed from discovery to early human trials in a decade. Most data is preclinical; human data is emerging.
The landmark discovery paper. MOTS-c was identified as the first mtDNA-encoded peptide with hormone-like properties. Injected MOTS-c improved insulin resistance in high-fat-diet mice, restored metabolic homeostasis, and reduced obesity — effects dependent on AMPK activation in skeletal muscle.
PMID: 25738455Demonstrated that MOTS-c is released from skeletal muscle during exercise and modulates adaptive gene expression. Mice treated with MOTS-c showed increased running performance comparable to exercise training, with enhanced mitochondrial biogenesis and fatty acid utilization. MOTS-c was proposed as a key mediator of the systemic exercise response.
PMID: 33741942Cross-sectional human study documenting significant age-related decline in circulating MOTS-c. Lower MOTS-c correlated with impaired insulin sensitivity, higher BMI, and reduced physical activity. Established MOTS-c as a potential aging biomarker. Study was correlational — did not establish causation.
PMID: 30936306A specific MOTS-c variant (K14Q) was found at higher frequency in East Asian populations and associated with longevity in centenarian cohorts. The variant MOTS-c had enhanced nuclear translocation and stronger AMPK activation, suggesting MOTS-c biology may be directly linked to extreme human longevity.
PMID: 34496222First-in-human Phase 1 safety trial in healthy older adults. MOTS-c was well-tolerated at multiple dose levels with no serious adverse events. Preliminary metabolic markers (fasting glucose, insulin, lipids) showed favorable trends at higher doses. Phase 2 trials ongoing as of 2026. Full trial results pending peer-reviewed publication.
ClinicalTrials.govDosing Information
All dosing information is from preclinical and early clinical research only. MOTS-c is not approved for human use. These figures are for educational reference.
MOTS-c is typically supplied lyophilized (freeze-dried powder). Reconstitution uses bacteriostatic water (1–2 mL per vial). Store reconstituted peptide at 2–8°C and use within 28 days. Never freeze reconstituted peptide. See our reconstitution guide for full protocol.
Research protocols have used morning dosing to align with natural diurnal MOTS-c rhythms. Pre-exercise administration has been explored in some protocols to augment the exercise response. No definitive optimal timing has been established in human trials.
Safety Profile
MOTS-c has a favorable preliminary safety profile in early human trials, but long-term data is limited. These considerations are based on available research.
Ideal Candidate
Based on current research mechanisms and early clinical data, certain profiles may benefit most — while others face heightened risk.
Key Takeaways
Related Compounds
MOTS-c belongs to the emerging mitochondrial-derived peptide (MDP) family. These related compounds target overlapping longevity and metabolic pathways.
24-amino acid mtDNA-encoded peptide discovered 2001. Neuroprotective, anti-apoptotic, declines ~40% with age. Alzheimer's and metabolic syndrome research.
Synthetic tetrapeptide that targets cardiolipin in the inner mitochondrial membrane. Phase 3 trials in Barth syndrome and heart failure. Most clinically advanced mitochondrial peptide.
Tetrapeptide bioregulator from the pineal gland that activates telomerase and regulates the melatonin/cortisol axis. Strong Russian longevity data in animal models and human studies.
C-terminal fragment of human growth hormone that activates fat metabolism via β3-adrenergic receptors. Metabolic research peptide with FDA GRAS status. Lipolysis without IGF-1 effects.
Supplies commonly used in peptide research protocols
As an Amazon Associate, MeetPeptide earns from qualifying purchases. Affiliate links help support MeetPeptide at no extra cost to you.
More Resources
This content is for educational and informational purposes only. MOTS-c is an investigational research peptide and is not approved by the FDA or any regulatory body for human therapeutic use. Nothing on this page constitutes medical advice, diagnosis, or treatment recommendation. Do not use MOTS-c or any research peptide based on information found here without consulting a qualified healthcare provider. Peptide research carries unknown risks. Individual responses vary. The information presented reflects the state of published research as of March 2026 and may not reflect subsequent findings.